NewsRoom Articles - BioMedWire (BMW)

FridayJul 24, 2026 10:30 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market

Regentis is targeting an estimated $3 billion U.S. cartilage repair market opportunity, supported by approximately 470,000 annual knee cartilage repair procedures and growing demand for regenerative medicine solutions. Regentis is advancing GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform designed to simplify treatment, improving patient outcomes while fitting current surgical workflows and supporting durable cartilage repair. These developments underscore the company's broader mission: To establish a new standard of care in cartilage repair through biomaterial-based regenerative technologies. Regentis Biomaterials (NYSE American: RGNT) is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather than simply…

FridayJul 24, 2026 10:00 am

Health Insurance Keeps 25% of US Employees Locked in Their Jobs

According to the findings of a recent poll conducted by Gallup and West Health, almost a quarter of employees within the U.S., or about 23 million individuals, remain doing jobs they would have otherwise left. They stay due to their desire to retain their health insurance. The data shows that “job lock” has been growing over the years and this latest survey indicates an increase of 8% from the number of people who reported being stuck in their jobs due to health insurance concerns in 2021. This comes as costs of healthcare are increasing to levels that are widely considered a crisis that needs to be fixed to tame rising medical…

ThursdayJul 23, 2026 10:30 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Advances Precision Oncology as Biomarker-Driven Cancer Gains Momentum

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. ONC010 is being developed for biomarker-selected cancers, aligning with the growing shift toward precision medicine The company is currently advancing ONC010 through manufacturing, and IND-enabling development programs Onco-Innovations combines targeted therapeutics, nanoparticle drug delivery, and AI-native discovery to address treatment-resistant cancers Cancer treatment is undergoing one of its most significant transformations in decades. Rather than relying on the traditional “one drug fits all” approach, oncology is increasingly embracing precision medicine. This strategy uses genomic testing and biomarker analysis to identify patients most likely to benefit from specific…

ThursdayJul 23, 2026 10:00 am

Recent Communicable Disease Outbreaks Highlight Gaps in Public Health Systems

The U.S. has recently had outbreaks of a number of infectious diseases, such as measles, mpox and HIV. These outbreaks have exposed critical gaps that exist in public health systems, according to Doctor Monica Gandhi, a medicine professor at UCSF (University of California, San Francisco). She explains that these outbreaks have highlighted the various vulnerabilities that exist in an environment that is already plagued by worsening staff shortages and funding shortfalls. She points out that vaccine coverage is dropping rapidly, especially over recent years. Such a trend is creating room for vaccine-preventable infectious diseases like measles to re-emerge and affect a lot more people. The current policies of…

WednesdayJul 22, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany

The company has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) supporting the proposed development strategy for its lead BiTAC(R)-TCE program. The regulatory feedback provides early guidance on the company’s biological rationale, safety assessments, and non-clinical development plan, for its novel therapeutic platform. VERAXA believes the advice helps reduce development uncertainty by providing greater clarity before advancing toward clinical studies. The company’s lead BiTAC(R)-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting. VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (“ADCs”) and other engineered…

TuesdayJul 21, 2026 11:15 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital. The company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change…

TuesdayJul 21, 2026 10:00 am

Study Finds No Evidence That Mobile Phones Can Cause Brain Cancer

For a long time, many people have claimed that using a mobile phone can cause brain cancer. These fears were so widespread that the World Health Organization commissioned teams to conduct 13 reviews aimed at establishing whether electromagnetic waves, such as those that enable mobile phones to work, had any health effects. The reviews were commissioned back in 2019. The World Health Organization hasn’t released its own findings of those reviews. However, a study that was published last week provides an analysis of the WHO-funded reviews. The researchers show that the available data doesn’t provide any evidence to suggest that electromagnetic waves released by mobile phones cause brain cancer or cancer of the neck…

TuesdayJul 21, 2026 9:45 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Hits Key Study Milestone as Early MS Imaging Data Shows Promising Signal

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide. Study is evaluating technique that allows researchers to tell the difference between nerve damage that may still be reversible and damage that is permanent. Quantum BioPharma reports two key developments: patient enrollment in the pilot study has reached its halfway mark and preliminary imaging data is encouraging. A key imaging study examining a novel approach to tracking multiple sclerosis (“MS”) has reached its halfway point in patient enrollment, with early results showing a…

MondayJul 20, 2026 9:45 am

Earth Science Tech Inc. (ETST) Continues to Optimize Operational and Financial Frameworks to Maintain Its Singular Position of Strength

Earth Science Tech, a strategic holding company in the healthcare, pharmacy, and telemedicine sector, is distinct from other OTC listed companies based on its record of strong results, hard real estate assets, vertical integration, and robust corporate structure The company has reported year-over-year growth in revenue and gross profits since fiscal year 2024, progress attributable to careful strategic and complementary investments and acquisitions, which have not added debt to its balance sheet Its acquisition of Avenvi created a subsidiary that develops, manages, and finances real estate and owns property that houses ETST’s Texas pharmacy Investopedia lists the lack of reliable…

FridayJul 17, 2026 10:00 am

Study Links Gut Microbial Metabolites to Enhanced Cancer Immunotherapy Sensitivity

Scientists have been racing to establish why some patients respond to cancer immunotherapy while others do not. A recent study has linked metabolites produced by certain bacteria in the gut to improved responses to cancer immunotherapy in patients. The study, whose findings were published in the journal Cell Reports Medicine, was conducted by a large team led by researchers at the University of Nebraska and Cedars-Sinai, alongside collaborators based at other academic institutions. Ramer-Tait from the University of Nebraska led the research effort. Previous research has variously linked gut microbiota to improved responses to cancer immunotherapy. However, no study had pinpointed a specific microbe or microbial metabolite linked to immunotherapy response improvements…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market

Health Insurance Keeps 25% of US Employees Locked in Their Jobs

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Advances Precision Oncology as Biomarker-Driven Cancer Gains Momentum

Recent Communicable Disease Outbreaks Highlight Gaps in Public Health Systems

VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions

Study Finds No Evidence That Mobile Phones Can Cause Brain Cancer

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Hits Key Study Milestone as Early MS Imaging Data Shows Promising Signal

Earth Science Tech Inc. (ETST) Continues to Optimize Operational and Financial Frameworks to Maintain Its Singular Position of Strength

Study Links Gut Microbial Metabolites to Enhanced Cancer Immunotherapy Sensitivity

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search